Publications

Detailed Information

Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study

DC Field Value Language
dc.contributor.authorLee, D H-
dc.contributor.authorKim, S-W-
dc.contributor.authorSuh, C-
dc.contributor.authorLee, J-S-
dc.contributor.authorLee, J H-
dc.contributor.authorLee, S-J-
dc.contributor.authorRyoo, B Y-
dc.contributor.authorPark, K-
dc.contributor.authorKim, J S-
dc.contributor.authorHeo, D S-
dc.contributor.authorKim, N K-
dc.date.accessioned2010-01-12T02:09:52Z-
dc.date.available2010-01-12T02:09:52Z-
dc.date.issued2007-09-08-
dc.identifier.citationAnn Oncol. 2008 Jan;19(1):123-7. Epub 2007 Sep 6.en
dc.identifier.issn1569-8041 (Electronic)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17823384-
dc.identifier.urihttps://hdl.handle.net/10371/29577-
dc.description.abstractBACKGROUND: Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). PATIENTS AND METHODS: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. RESULTS: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. CONCLUSION: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.subjectAgeden
dc.subjectAntineoplastic Agents, Phytogenic/pharmacokinetics/*therapeutic useen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/therapeutic useen
dc.subjectCamptothecin/adverse effects/*analogs &en
dc.subjectderivatives/pharmacokinetics/therapeutic useen
dc.subjectCarcinoma, Small Cell/*drug therapyen
dc.subjectDNA Topoisomerases, Type I/antagonists & inhibitorsen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Proteins/antagonists & inhibitorsen
dc.subjectNeutropenia/chemically induceden
dc.subjectSalvage Therapyen
dc.subjectTreatment Outcomeen
dc.titleBelotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II studyen
dc.typeArticleen
dc.identifier.doi10.1093/annonc/mdm437-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share